Dennis Levinson
Internal Medicine · Chicago, ILNPI 1720050016
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,140 of the $4,550 with a category attached, or 91.0%. Pfizer accounts for 92.5% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $4,287 and has fallen 96.4% since, to $156 in 2022. Among internal medicine clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 29 payments — averaging $156.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$4K
- Biogen$136
- Mallinckrodt Enterprises LLC$48
- Amgen$45
- Boehringer Ingelheim$33
- GSK$24
- plus $57 from 3 others
Across 860 payments — averaging $29,619 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$9.3M
- AstraZeneca$7.7M
- Novartis$2.2M
- Astrazeneca UK Limited$1.3M
- AbbVie$993K
- Pfizer$905K
- plus $3.1M from 12 others
What the payments were for
- Speaking & faculty fees$4,14091%
- Food & beverage$2746%
- Education$1363%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 6 | $4,207 |
| Biogen | 14 | $136 |
| Mallinckrodt Enterprises LLC | 2 | $48 |
| Amgen | 2 | $45 |
| Boehringer Ingelheim | 1 | $33 |
| GSK | 1 | $24 |
| Antares Pharma, Inc. | 1 | $21 |
| Novartis | 1 | $20 |
| Johnson & Johnson | 1 | $16 |
How this compares
$4,550 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xeljanz XrTofacitinib Citrate | 16 | $89,137 |
| Colchicine | 14 | $1,895 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 29 | $1,266 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $968 |
| Gabapentin | 36 | $708 |
| Ondansetron Hcl | 15 | $583 |
| Diphenhydramine Hcl | 11 | $500 |
| Finasteride | 13 | $262 |
| Hydrochlorothiazide | 24 | $225 |
| Prednisone | 34 | $224 |
| Celecoxib | 13 | $210 |
| Allopurinol | 13 | $204 |
| Sumatriptan Succinate | 13 | $176 |
| MethotrexateMethotrexate Sodium | 12 | $160 |
| Amlodipine Besylate | 18 | $149 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Chicago
- Merle DiamondChicago$1.1M
- Robert KushnerChicago$516K
- Romeo UrsuaChicago$420K
- Peter O DonnellChicago$318K
- George UrbanChicago$258K
- Kristen PallokChicago$256K
- George NissanChicago$252K
- Luke LaffinChicago$162K
- Daniel CatenacciChicago$161K
- Hiren ShahChicago$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.